---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-308803"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T01:44:13.958073+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lantheus closes strategic collaboration & license agreements with POINT Biopharma for PNT-2002 and PNT-2003

## Summary
- Paid $250M upfront for PNT-2002 (prostate cancer therapy); $10M upfront for PNT-2003 (neuroendocrine tumor therapy).
- Potential regulatory milestones up to $281M (PNT-2002) and $34.5M (PNT-2003); sales milestones up to $1.28B and $275M, respectively.
- PNT-2002 royalties: 20% after $500M cumulative gross profit; PNT-2003 royalties: 15% of net sales.
- Agreements became effective Dec 20, 2022, after HSR waiting period expired.
- Lantheus will develop and commercialize both candidates worldwide except certain Asian countries.

## SEC filing metadata
- accession: 0001193125-22-308803
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/0001193125-22-308803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/d435614d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-308803
- JSON: https://secwatch.observer/filing/0001193125-22-308803.json
- Plain text: https://secwatch.observer/filing/0001193125-22-308803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.